Skip to main content
Top
Gepubliceerd in: Child Psychiatry & Human Development 3/2011

01-06-2011 | Original Article

Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial

Auteurs: Seyed-Hesameddin Abbasi, Shahram Heidari, Mohammad-Reza Mohammadi, Mina Tabrizi, Ali Ghaleiha, Shahin Akhondzadeh

Gepubliceerd in: Child Psychiatry & Human Development | Uitgave 3/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

The objective of this study was to test whether a previous observed Acetyl-L-carnitine (ALC) treatment effect could be repeated in an ALC adjunctive therapy treatment trial of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. This was a six-week, randomized clinical trial undertaken in an outpatient child and adolescent clinic. Subjects included 40 outpatients (28 boys and 12 girls) between the ages of 7–13 who met the DSM-IV-TR diagnostic criteria for ADHD. All study subjects were randomly assigned to receive treatment using capsules of ALC doses ranging from 500 to 1,500 mg/day depending on the weight of the child plus methylphenidate at a dose of 20–30 mg/day depending on weight or Placebo plus methylphenidate at a dose of 20–30 mg/day depending on weight. The principal measure of outcome was the Teacher and Parent attention deficit/hyperactivity disorder Rating Scale- IV. No difference was observed between the two groups on the Parent and Teacher Rating Scale scores (df = 1; F = 0.10; P = 0.74 and df = 1; F = 0.22; P = 0.63 respectively). Side effects consisting of headache and irritability were observed more frequently in the methylphenidate plus placebo group. The results of this study do not support the application of ALC as an adjunctive therapy to methylphenidate in children and adolescents with ADHD.
Literatuur
1.
go back to reference Noorbala AA, Akhondzadeh S (2006) Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. Arch Iranian Med 9:374–380 Noorbala AA, Akhondzadeh S (2006) Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy. Arch Iranian Med 9:374–380
2.
go back to reference Mohammadi MR, Akhondzadeh S (2007) Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Exp Rev Neurotrapeutics 7:195–201CrossRef Mohammadi MR, Akhondzadeh S (2007) Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Exp Rev Neurotrapeutics 7:195–201CrossRef
3.
go back to reference Curatolo P, Paloscia C, D’Agati E, Moavero R, Pasini A (2009) The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 13:299–304PubMedCrossRef Curatolo P, Paloscia C, D’Agati E, Moavero R, Pasini A (2009) The neurobiology of attention deficit/hyperactivity disorder. Eur J Paediatr Neurol 13:299–304PubMedCrossRef
4.
go back to reference Dopheide JA, Pliszka SR (2009) Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29:656–679PubMedCrossRef Dopheide JA, Pliszka SR (2009) Attention-deficit-hyperactivity disorder: an update. Pharmacotherapy 29:656–679PubMedCrossRef
5.
go back to reference Adriani W, Rea M, Baviera M, Invernizzi W, Carli M, Ghirardi O, Caprioli A, Laviola G (2004) Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacology (Berl) 176:296–304CrossRef Adriani W, Rea M, Baviera M, Invernizzi W, Carli M, Ghirardi O, Caprioli A, Laviola G (2004) Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats. Psychopharmacology (Berl) 176:296–304CrossRef
6.
go back to reference Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 1033:30–41PubMedCrossRef Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 1033:30–41PubMedCrossRef
7.
go back to reference Van Oudheusden LJ, Scholte HR (2002) Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 67:33–38PubMedCrossRef Van Oudheusden LJ, Scholte HR (2002) Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 67:33–38PubMedCrossRef
8.
go back to reference Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D’Iddio S, Calvani M, Neri G (2008) A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 146:803–812PubMed Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D’Iddio S, Calvani M, Neri G (2008) A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 146:803–812PubMed
9.
go back to reference Arnold LE, Amato A, Bozzolo H, Hollway J, Cook A, Ramadan Y, Crowl L, Zhang D, Thompson S, Testa G, Kliewer V, Wigal T, McBurnett K, Manos M (2007) Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 17:791–802PubMedCrossRef Arnold LE, Amato A, Bozzolo H, Hollway J, Cook A, Ramadan Y, Crowl L, Zhang D, Thompson S, Testa G, Kliewer V, Wigal T, McBurnett K, Manos M (2007) Acetyl-L-carnitine (ALC) in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 17:791–802PubMedCrossRef
10.
go back to reference American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision (DSMIV- TR). American Psychiatric Association, WashingtonCrossRef American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision (DSMIV- TR). American Psychiatric Association, WashingtonCrossRef
11.
go back to reference Ghanizadeh A, Mohammadi MR, Yazdanshenas A (2006) Psychometric properties of the Farsi translation of the Kiddie schedule for affective disorders and Schizophrenia- present and lifetime version. BMC Psychiatry 15(6):10CrossRef Ghanizadeh A, Mohammadi MR, Yazdanshenas A (2006) Psychometric properties of the Farsi translation of the Kiddie schedule for affective disorders and Schizophrenia- present and lifetime version. BMC Psychiatry 15(6):10CrossRef
12.
go back to reference DuPaul G, Power T, Anastopoulos A, Reid R (1998) ADHD rating scale-IV. Guilford, New York DuPaul G, Power T, Anastopoulos A, Reid R (1998) ADHD rating scale-IV. Guilford, New York
13.
go back to reference Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H (2003) Selegiline in the treatment of attention-deficit hyperactivity disorder in children: a double-blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27:841–845PubMedCrossRef Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H (2003) Selegiline in the treatment of attention-deficit hyperactivity disorder in children: a double-blind and randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27:841–845PubMedCrossRef
14.
go back to reference Akhondzadeh S, Mohammadi MR, Khademi M (2004) Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 8(4):9CrossRef Akhondzadeh S, Mohammadi MR, Khademi M (2004) Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry 8(4):9CrossRef
15.
go back to reference Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S (2008) Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32:145–149PubMedCrossRef Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S (2008) Modafinil as a treatment for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 32:145–149PubMedCrossRef
16.
go back to reference Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S (2009) A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168:234–237PubMedCrossRef Kahbazi M, Ghoreishi A, Rahiminejad F, Mohammadi MR, Kamalipour A, Akhondzadeh S (2009) A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 168:234–237PubMedCrossRef
17.
go back to reference Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S (2010) Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 34:76–80PubMedCrossRef Salehi B, Imani R, Mohammadi MR, Fallah J, Mohammadi M, Ghanizadeh A, Tasviechi AA, Vossoughi A, Rezazadeh SA, Akhondzadeh S (2010) Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 34:76–80PubMedCrossRef
18.
go back to reference Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F, Akhondzadeh S (2010) Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol 25:530–535PubMed Zarinara AR, Mohammadi MR, Hazrati N, Tabrizi M, Rezazadeh SA, Rezaie F, Akhondzadeh S (2010) Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Hum Psychopharmacol 25:530–535PubMed
19.
go back to reference Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2004) Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(suppl 1):102–116 Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2004) Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(suppl 1):102–116
20.
go back to reference Arduini A, Denisova N, Virmani A, Avrova N, Federici G, Arrigoni-Martelli E (1994) Evidence for the involvement of carnitine dependent long-chain acyltransferases in neuronal triglyceride and phospholipid fatty acid turnover. J Neurochem 62:1530–1538PubMedCrossRef Arduini A, Denisova N, Virmani A, Avrova N, Federici G, Arrigoni-Martelli E (1994) Evidence for the involvement of carnitine dependent long-chain acyltransferases in neuronal triglyceride and phospholipid fatty acid turnover. J Neurochem 62:1530–1538PubMedCrossRef
21.
go back to reference Richardson AJ, Ross MA (2000) Fatty acid metabolism in neurodevelopmental disorder: a new prospective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukotr Essent Acids 63:1–9CrossRef Richardson AJ, Ross MA (2000) Fatty acid metabolism in neurodevelopmental disorder: a new prospective on associations between attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukotr Essent Acids 63:1–9CrossRef
22.
go back to reference Calvani M, Arrigoni-Martelli E (1999) Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 21:1–6PubMed Calvani M, Arrigoni-Martelli E (1999) Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 21:1–6PubMed
Metagegevens
Titel
Acetyl-L-Carnitine as an Adjunctive Therapy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Placebo-Controlled Trial
Auteurs
Seyed-Hesameddin Abbasi
Shahram Heidari
Mohammad-Reza Mohammadi
Mina Tabrizi
Ali Ghaleiha
Shahin Akhondzadeh
Publicatiedatum
01-06-2011
Uitgeverij
Springer US
Gepubliceerd in
Child Psychiatry & Human Development / Uitgave 3/2011
Print ISSN: 0009-398X
Elektronisch ISSN: 1573-3327
DOI
https://doi.org/10.1007/s10578-011-0220-y

Andere artikelen Uitgave 3/2011

Child Psychiatry & Human Development 3/2011 Naar de uitgave